Streetwise Articles

Now Cashed Up, Biopharma to Advance Cholesterol-Lowering Therapy
Source: Streetwise Reports  (3/23/19)
A ROTH Capital Partners report reviewed this New Jersey firm's plans for its lead asset. More >

Several Data Catalysts Expected in 2019 for 'Underappreciated Story'
Source: Streetwise Reports  (3/22/19)
An H.C. Wainwright & Co. report discussed what those are and why they could impact the biotech's valuation. More >

Rare Diseases Biotech Provides Opportunity
Source: Streetwise Reports  (3/21/19)
A ROTH Capital Partners report discussed why the stock price is at its current level and noted upcoming catalysts for the company. More >

Tech Firm to Offer Solution to Inefficient, Expensive Health Clinic Business Model
Source: Streetwise Reports  (3/20/19)
The company will roll out virtual, remote medical services to change how primary care practices are run. More >

Biopharma Expected to Bring 'Two First-in-Class Antibiotics to Market in 2019'
Source: Streetwise Reports  (3/19/19)
The likely timelines for approval and commercialization of each drug are discussed in an H.C. Wainwright report. More >

Cannabis Firm Announces Brand for Recreational Aficionados
Source: Streetwise Reports  (3/19/19)
This Canadian company intends to next launch a marketing campaign for the new product suite. More >

Steve Palmer

5 Small-Caps on Fund Manager Steve Palmer's Radar Screen
Source: Streetwise Reports  (3/19/19)
Steve Palmer, Founding Partner, President and Chief Investment Officer for AlphaNorth Asset Management, talks about a handful of companies in diverse industries that have his attention. More >

Antibody Therapeutics Developer to Present at March Alzheimer's/Parkinson's Conference
Source: Streetwise Reports  (3/19/19)
The biotech was selected to discuss its antibodies that selectively target toxic forms of alpha-synuclein. More >

Health Tech Firm Completes Enrollment for Female Sexual Function Trial
Source: Streetwise Reports  (3/15/19)
A Ladenburg Thalmann report reviewed the study design and purpose. More >

Disruptive Delivery Company Signs Deal for Cannabis Distribution
Source: Clive Maund for Streetwise Reports  (3/15/19)
Technical analyst Clive Maund discusses both the fundamentals and technicals for this company that just signed a cannabis distribution agreement with a Vancouver-based retailer. More >

Logistics Firm Moves Further Toward Becoming 'Uber of Cannabis for Canada'
Source: Streetwise Reports  (3/14/19)
This company forges partnerships with cannabis companies to deliver, within an hour, their products to customers. More >

Tech Firm Launches Augmented Reality Showcase for Legal Cannabis Products
Source: Streetwise Reports  (3/14/19)
The new platform promises to provide a unique e-commerce experience in the legal cannabis industry, combining customer education and support for online transactions. More >

Ron Struthers

Marijuana: Up in Smoke
Source: Ron Struthers for Streetwise Reports  (3/13/19)
Sector expert Ron Struthers takes a look at a spectrum of cannabis companies, including one company that's gone from a high to a downer, a sector leader, and a firm that promotes CBDs as good for sex. More >

Analyst: Biotech to Have 'Eventful Year' with Data Readouts in Three Indications
Source: Streetwise Reports  (3/12/19)
This California company expects results from clinical trials in liver disease and psoriasis in 2019. More >

Large US Market Now Open to Livestock Feed Antibiotic Replacement
Source: Streetwise Reports  (3/11/19)
Proprietary OxC-beta livestock feed supplement can supplant the need for maintenance antibiotics. More >

Coverage Initiated on Cancer Vaccine Firm
Source: Streetwise Reports  (3/9/19)
An H.C. Wainwright & Co. report explained the reasons for its "bullish view" on this California-based life sciences company. More >

Coverage Initiated on Producer of Hemp-Derived Cannabidiol Products
Source: Streetwise Reports  (3/9/19)
A ROTH Capital Partners report presented the reasons for investing in this company. More >

Augmented Reality and Healthcare Tech Firms to Collaborate
Source: Streetwise Reports  (3/8/19)
The companies aim to combine their expertise to co-create immersive and compelling instructive medical tools. More >

U.S. Biotech Makes 'The Acquisition We Were Waiting For'
Source: Streetwise Reports  (3/6/19)
By tucking in this retinal gene therapy firm, the Massachusetts-based company gains assets and synergy. More >

Firm Launches App to Help Physicians Provide Virtual Counseling
Source: Streetwise Reports  (3/5/19)
This new initiative combines emerging technologies and human skill-based expertise. More >

After Financing Close, Biotech's Subsidiary to Operate Independently
Source: Streetwise Reports  (3/5/19)
An H.C. Wainwright & Co. report explained the purpose of the funding and how any resulting developments would positively impact the former parent company. More >

Biotech to Launch Preclinical Studies of Antibody in Eight Cancer Types
Source: Streetwise Reports  (2/27/19)
This company's new trials, preferred dosing and upcoming biologics license application submission are discussed in an H.C. Wainwright & Co. report. More >

FDA Grants Breakthrough Status to Biopharma's Lead Candidate for Liver Disease
Source: Streetwise Reports  (2/25/19)
The California firm's most advanced asset is advancing through Phase 2b, according to a ROTH Capital Partners report. More >

Livestock Feed Developer Partners to Initiate Product Sales in the U.S.
Source: Streetwise Reports  (2/22/19)
The arrangement represents this Canadian life sciences firm's entrée into a significant market. More >

Biopharma's Foundation Provides for Downside Protection, Upside Realization
Source: Streetwise Reports  (2/20/19)
An H.C. Wainwright & Co. report described this Israeli firm's solid revenue picture and addressed the undervaluation of a key therapeutic candidate. More >

Showing Results: 1 to 25 of 1038 Next

Notable Quotes

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"DRRX's Posimir comes back in play."
– Ed Arce, H.C. Wainwright & Co.